Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2015. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure data as of December 31, 2014:
- Issued Share Capital: 5,355,297,232 Ordinary Shares of 25p each.
- Treasury Shares: 491,515,950 Ordinary Shares.
- Total Voting Rights: 4,863,781,282.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a static notification of share capital status as of the end of 2014.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is limited to the disclosure of voting rights to assist shareholders in determining notification requirements under the Financial Conduct Authority's rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,863,781,282) against the issued share capital and treasury holdings.
- Confirm the date of the capital structure snapshot (December 31, 2014).
- Check subsequent filings for financial performance data, as this specific 6-K contains no operational or financial results.